![Gene Napolitano](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gene Napolitano
Keine laufenden Positionen mehr
Profil
Gene Napolitano worked as a Director of Project Management & Drug Discovery at Signature BioScience, Inc., a Project Leader at Telik, Inc., and a Vice President of Operations at Iconix Biosciences, Inc. He also worked as a Principal at IGEN International, Inc. Dr. Napolitano holds a doctorate degree from New York University and an undergraduate degree from State University of New York at Binghamton.
Ehemalige bekannte Positionen von Gene Napolitano
Unternehmen | Position | Ende |
---|---|---|
Telik, Inc.
![]() Telik, Inc. Pharmaceuticals: MajorHealth Technology Telik, Inc. is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. Its TELINTRA product is used for treatment of cytopenias due to myelodysplastic syndrome and chemotherapy. The company's product candidates were discovered using its proprietary drug discovery technology TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Telik was founded in September 1988 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | - |
Signature BioScience, Inc.
![]() Signature BioScience, Inc. Miscellaneous Commercial ServicesCommercial Services Signature BioScience, Inc. discovers new drugs by applying its parallel target and compound selection process. The private company is based in Hayward, CA and has subsidiaries in the United States. The company was founded by Andrew Peter Sandham and John Hefti. | Corporate Officer/Principal | - |
IGEN International, Inc.
![]() IGEN International, Inc. Medical SpecialtiesHealth Technology IGEN International, Inc. develops and markets biological testing systems that incorporate its proprietary electrochemiluminescence technology for used in drug discovery, diagnostic products development as well as food and environmental safety testing. The company was founded in 1982 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Iconix Biosciences, Inc.
![]() Iconix Biosciences, Inc. BiotechnologyHealth Technology Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix. | Geschäftsführer | - |
Ausbildung von Gene Napolitano
State University of New York at Binghamton | Undergraduate Degree |
New York University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Iconix Biosciences, Inc.
![]() Iconix Biosciences, Inc. BiotechnologyHealth Technology Iconix Biosciences is a multi-disciplinary company that integrates the skills and knowledge necessary for the creation of the world's largest toxicogenomics database of microarray and pharmacology data (DrugMatrix) with the informatics expertise and computer skills required to mine and interpret this vast body of information. Based on the data in DrugMatrix, Iconix has developed a library of Drug Signatures, genomic biomarkers that are predictive of specific toxicological endpoints and mechanisms of action. DrugMatrix and Drug Signatures provide a uniform source of molecular toxicology information, analytical tools, data mining algorithms and biomarkers to optimize drug candidates and predict their potential efficacy and toxicity before they advance to expensive preclinical and clinical development studies. Iconix's platform includes an integrated database architecture (IXIS) to bridge genomics and drug design, novel bio and chemoinformatics software, and advanced expression array and cellular expression assay development capabilities. This technology platform is coupled with an unparalled group of molecular toxicologists and bioinformaticians with years of experience in applying the tools and contextual data to provide clients with answers to critical scientific questions. Iconix has focused these capabilities on a line of products, licenses, services, and long-term collaborations. Iconix provides reports on customer compounds to classify them and help prioritize and select the best leads for advancement at all stages of discovery. Iconix has also entered exclusive alliances with collaborators to apply toxicogenomics data and know-how to customized drug discovery and development projects. Founded in 1998 by distinguished scientists and pharmaceutical industry professionals, Iconix has won the backing of some of the highest profile venture capitalists in the biotechnology and information technology industries. Iconix has also established alliances with leading global technology companies for the development and commercialization of its products, including MDS Pharma Services, Spotfire, Amersham Biosciences, MDL Information Systems, and Affymetrix. | Health Technology |
Signature BioScience, Inc.
![]() Signature BioScience, Inc. Miscellaneous Commercial ServicesCommercial Services Signature BioScience, Inc. discovers new drugs by applying its parallel target and compound selection process. The private company is based in Hayward, CA and has subsidiaries in the United States. The company was founded by Andrew Peter Sandham and John Hefti. | Commercial Services |
IGEN International, Inc.
![]() IGEN International, Inc. Medical SpecialtiesHealth Technology IGEN International, Inc. develops and markets biological testing systems that incorporate its proprietary electrochemiluminescence technology for used in drug discovery, diagnostic products development as well as food and environmental safety testing. The company was founded in 1982 and is headquartered in Gaithersburg, MD. | Health Technology |
Telik, Inc.
![]() Telik, Inc. Pharmaceuticals: MajorHealth Technology Telik, Inc. is an innovative biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. Its TELINTRA product is used for treatment of cytopenias due to myelodysplastic syndrome and chemotherapy. The company's product candidates were discovered using its proprietary drug discovery technology TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Telik was founded in September 1988 and is headquartered in Palo Alto, CA. | Health Technology |